Terapi Favipiravir Pada Subyek Covid-19 Derajat Sedang Tanpa Gangguan Liver Di RS Pusat Infeksi Prof Dr Sulianti Saroso

Brisbane, Hastutik Cairn and Rahem, Abdul and Purnamayanti, Anita and Rusli, Adria (2022) Terapi Favipiravir Pada Subyek Covid-19 Derajat Sedang Tanpa Gangguan Liver Di RS Pusat Infeksi Prof Dr Sulianti Saroso. Jurnal Ilmiah Ibnu Sina, 7 (2). pp. 261-269. ISSN 2502-647X; e-ISSN: 2503-1902

	PDF H.C. Brisbane_A. Rahem_Anita Purnamayanti_880-Article Text-4208-1-10-20221031.pdf Download (1MB)
	PDF Penerimaan Artikel Untuk Dipublikasikan Hastutik Cairn Brisbane.pdf Download (127kB)

Abstract

Wabah virus corona yang pertama kali berjangkit pada Desember 2019 di Wuhan, China, saat ini telah ditetapkan oleh World Health Organization (WHO) sebagai pandemi dan dikenal dengan Corona Virus Infection Disease 2019 (Covid-19). Penelitian ini bertujuan untuk mendeskripsikan profil terapi favipiravir pada pasien rawat inap COVID-19 sedang tanpa gangguan hati di RSUD Prof. dr. RS Pusat Infeksi Sulianti Saroso. Desain penelitian ini adalah penelitian observasional yang dilakukan secara retrospektif. Semua pasien dalam penelitian ini menerima dosis muatan favipiravir 2 kali sehari 1600 mg pada hari pertama, dan dua kali sehari 600 mg mulai hari ke-2 terapi. Hasil penelitian adalah 81 pasien rawat inap Covid-19 sedang tanpa riwayat atau saat ini sedang mengalami gangguan liver yang dirawat di rumah sakit pada periode Oktober 2020 - Juli 2021, yang terbanyak berjenis kelamin perempuan (56%). Cara masuk rumah sakit terbanyak adalah rujukan mandiri ke Prof. dr. Rumah Sakit Pusat Infeksi Sulianti Saroso (83%), rujukan pelayanan primer (Puskesmas) (12%), dan rumah sakit rujukan lainnya (5%). Tidak terdapat penyakit penyerta pada 74,1% subjek. Dari 25,9% subjek dengan penyakit penyerta, sebagian besar pasien menderita hipertensi (29%); hipertensi, dan penyakit kardiovaskular (17%). diabetes (12%); diabetes dan hipertensi (12%); asma (12). Tidak terdapat subjek yang mengalami peningkatan transaminase hati (ALT, AST), maupun ALP dan bilirubin total. Delapan puluh satu pasien sembuh (12%) dengan hasil tes PCR negatif atau membaik (88%) pada akhir terapi The outbreak of the corona virus which first contracted in December 2019 in Wuhan, China; Currently it has been designated by the World Health Organization (WHO) as a pandemic and is known as Corona Virus Infection Disease 2019 (Covid-19). This study aimed to describe the profile of favipiravir therapy in moderate COVID-19 inpatients without liver impairment at Prof. dr. Sulianti Saroso Infection Center Hospital. The design of this study was an observational study conducted retrospectively. All the patients in this research were received favipiravir loading dose of 1600 mg bid on the first day, and 600 mg bid starting on the day-2 of therapy. The results of the research were 81 moderate Covid-19 inpatients without history or recent liver impairment who were hospitalized in the period October 2020 - July 2021 dominating by female gender (56%). Mode of hospital admission were self-referral to Prof. dr. Sulianti Saroso Infection Center Hospital (83%), primary care (Puskesmas) referral (12%), and other hospital referral (5%). There were no comorbidity in 74,1% of the subjects. Among 25,9% subjects with comorbidity, most of the patients suffered from hypertension (29%); hypertension, and cardiovascular disease (17%). diabetes (12%); diabetes and hypertension (12%); Asthma (12). None of the subjects experienced increased in liver transaminases (ALT, AST), nor ALP and total bilirubin. Eighty-one patients were either cured (12%) with negative PCR test results or improved (88%) at the end of the therapy.

Item Type:	Article
Uncontrolled Keywords:	Favipiravir, Moderate covid-19, Liver, Inpatient
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Postgraduate Programs > Master Program in Clinical Pharmacy
Depositing User:	Hastutik Cairn Brisbane
Date Deposited:	04 Feb 2022 07:49
Last Modified:	02 Jan 2023 06:01
URI:	http://repository.ubaya.ac.id/id/eprint/41170

Actions (login required)

View Item